Fierce Healthcare March 15, 2024
On Thursday, the Food and Drug Administration announced its approval of the first ever therapeutic treatment targeting metabolic dysfunction-associated steatohepatitis (MASH).
This represents a pivotal moment in healthcare and calls for a celebration.
This new therapeutic for advanced-stage liver disease is significant because, until now, diet and exercise were the only available treatment options.
It’s true this drug will be game-changing for physicians. More importantly, it will be life-changing for patients.
As we celebrate this milestone, we must ask ourselves: Are we truly prepared for when this drug hits the market?
The dire current reality
Nearly 1 in 4 Americans suffer from metabolic dysfunction–associated steatotic liver disease. Of that population, 20% have the more advanced disease form, MASH.
The more...
Today's Sponsors
Today's Sponsor